Foreignexchange Gets High Marks on Client Survey

Newton, MA, February 12, 2011 – For the tenth year in a row, clients of ForeignExchange Translations say they are very satisfied with the quality and service they have received, and an astonishing 96% say they would gladly recommend ForeignExchange to other companies looking for a translation and localization provider.

ForeignExchange is a leading provider of specialized language services to companies within the medical device, pharmaceutical and biotech sectors. Since the year 2000, ForeignExchange has conducted a comprehensive annual survey of its clients, to assist in determining the focus of its ongoing service improvement efforts.

The 2010 survey results are now in, with an overall satisfaction rating of 5.37 out of 6. When comparing ForeignExchange to other translation and localization providers with whom they have worked, clients stated their belief that ForeignExchange is doing a better job in terms of quality, price, customer service and technical knowledge.

The 2010 survey was sent to 369 clients who signed off on translation projects within the calendar year. 92 surveys were completed, for a response rate of 25%. To obtain a copy of the survey results, please visit: http://info.fxtrans.com/css_report/

About ForeignExchange Translations

ForeignExchange Translations, Inc. is redefining the delivery of foreign-language services to the medical device, biotechnology, and pharmaceutical industries. ForeignExchange’s solutions are based on its proprietary Multilingual Compliance Process, combining expert linguists, best-of-breed technology, and measurable translation quality in a robust and scalable process that can be deployed in multiple languages simultaneously. ForeignExchange provides Internet globalization, software localization, and technical translation solutions to clients such as Abbott (NYSE:ABT), Pfizer (NYSE:PFE), GlaxoSmithKline (NYSE:GSK), Baxter (NYSE:BAX), and Medtronic (NYSE:MDT). For more information, please visit www.fxtrans.com

MORE ON THIS TOPIC